0:19:26 · Tycho Peterson, Jefferies · Clinical consumables
Were there any stocking orders in clinical, and is the implied Q4 clinical growth the right jumping-off point for next year?
Management said Q3 looked like Q2 with 14-15 % clinical growth and mid-teens for the year, and that Q4 consumables expectations rose on strong placements. — Jacob Thaysen, Ankur Dhingra
0:21:09 · Vijay Kumar, Evercore ISI · 2027 outlook
What is the right 2027 framework, are the long-range targets intact, and could instruments become a headwind?
Management will give full 2027 guidance on the Q4 call, but sees clinical as a lasting growth driver, multi-omics and AI as added opportunities, and elevated X placements continuing to support growth. — Jacob Thaysen
0:23:28 · Doug Shenko, UBS · X placements
Is the NovaSeq X placement strength a pull-forward, and how does demand split between capacity expansion and replacements?
Management saw no pull-forward and attributed demand to a healthy clinical market, sequencing-intensive new assays and customer confidence in the X platform's innovation. — Jacob Thaysen
0:25:55 · Tuneet Souda, Learink · Pricing and volume
Are new instruments driving lower cost per gigabase and elasticity, and is the high single-digit 2027 framework intact?
The CEO said the X transition lowered price but raised volume as customers build bigger assays, and that Illumina remains on track for high single-digit growth in 2027. — Jacob Thaysen
0:29:13 · Sabu Nandi, Guggenheim · New products, margins
Can new products still add one to two points of growth in 2027, and is a 25% exit operating margin the right launch point?
Management said the new-asset and data growth driver is playing out, including multi-omics and SomaLogic, and that margins are up 400 basis points, with more to come. — Jacob Thaysen
0:31:24 · Luke Sergot, Darkleys · Clinical growth
How does clinical sequencing play out as liquid biopsy players grow and convert to the X?
The CEO pointed to the razor-blade model, in which each X placed generates future consumables, and said clinical remains strong with many applications still coming online. — Jacob Thaysen, Ankur Dhingra
0:34:04 · Dal Narias, SIPO · AI and pricing
Does cheaper genome pricing force Illumina to revisit price elasticity to win large AI and virtual-cell projects?
The CEO said AI opportunity goes well beyond whole-genome pricing, since Illumina can build multi-omic datasets across genome, transcriptome, methylome and proteome, and it is comfortable with elasticity. — Jacob Thaysen
0:37:04 · Dave Westenberg, Piper Sandler · Clinical pricing
How fast can clinical grow and what discounting should be expected from large customers in 2027-2029?
Management said customers are building bigger assays for therapy selection, MRD and MCED, that Illumina grows with them, and that US clinical growth is well above 14 %. — Jacob Thaysen, Ankur Dhingra
0:40:26 · Kyle Mixon, Canaccord Genuity · Long-term growth
Is there upside to the high single-digit growth target, possibly toward double digits with margins in the high 20s?
The CEO said upside is not impossible given clinical, multi-omics, research recovery and AI, but Illumina wants to first show high single-digit growth. — Jacob Thaysen
0:42:39 · Dan Lennon, RBC · BioInsight
When will BioInsight become visible in the P&L?
Management expects some visibility in 2027, led by the Billion Cell Atlas, and said new products and BioInsight should add one to two points of growth. — Jacob Thaysen, Ankur Dhingra
0:45:11 · Casey Woodring, JPMorgan · Q4 and China
How much does the extra Q4 week add, is a budget flush expected, and has anything changed with China?
The extra week falls over the holidays with minimal revenue impact, no budget flush is assumed, and Illumina is pleased to be back to growth in China while it assesses new trade restrictions on competitors. — Jacob Thaysen, Ankur Dhingra
0:48:27 · Dan Brennan, TD Cowen · AI business model
Is the AI opportunity mainly services or instrument placements, and what was NovaSeq X pricing in the quarter?
Management expects a blend, with a large service opportunity in generating standardized datasets plus instrument demand from customers who want to add their own data, and the Billion Cell Atlas spans multi-omic combinations. — Jacob Thaysen, Ankur Dhingra
0:52:23 · Dave Westenberg, Piper Sandler · China
What drove China growth in the quarter and how should China be viewed going forward?
The CEO said Illumina is committed to China, focused on supporting customers and innovation, and sees a big opportunity there. — Jacob Thaysen
0:53:18 · Tysha Peterson, Jefferies · Leasing
Is the rise in operating lease interest limited to research, or could it spread to clinical?
Lease and reagent rental demand is growing in research and in mid-size clinical labs, though not among the largest clinical customers who are expanding capacity. — Ankur Dhingra